Epitalon for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Sonnet 5.5

Also known as: Epithalon, Epitalone, Epithalone, AEDG, Ala-Glu-Asp-Gly

Motivation

Epitalon (also written epithalon) is a synthetic chain of four amino acids modeled on material extracted from the pineal gland, a small brain structure that helps set the body’s day-night rhythm. It is marketed in longevity circles as a way to influence biological aging and is sold mainly as an injectable research product.

The compound was developed in Russia several decades ago from an animal pineal extract, and most of the published work comes from the group that created it. That work has examined its effects on the enzyme that rebuilds the protective caps on chromosome ends, on melatonin production, and on lifespan in laboratory animals. Recently, a United States advisory panel debated whether pharmacies may prepare it, which has drawn fresh public attention.

This review examines what is known about epitalon for health and longevity: how it is thought to work, how strong and how independent the human and animal evidence is, which risks have been reported or are theoretically possible, how it is used and sourced in practice, and what remains unresolved for health- and longevity-oriented adults considering it.

Benefits - Risks - Protocol - Conclusion

These sources give overviews of epitalon, a peptide (short chain of amino acids), ranging from independent laboratory work to its developer’s own summaries.

Only four sources qualified as high-level overviews of epitalon, so the list is not padded with marginally relevant content; lifespan.io carries only a news report on one mouse egg-cell study, which is not an overview. No substantial epitalon content was found from Rhonda Patrick, Peter Attia, Chris Kresser, or Life Extension Magazine. On-site searches on foundmyfitness.com and peterattiamd.com returned no results; foundmyfitness.com hosts only a one-minute 2016 community post, a social-style item that is excluded. chriskresser.com returned one 2019 interview with a single passing sentence on epitalon, which is not substantial coverage. The lifeextension.com search page could not be displayed with results (access denied or empty shell).

Grokipedia

Epitalon

AI-generated encyclopedia entry covering history, chemistry, proposed mechanisms, biological effects, safety, and regulatory status; it states that the human evidence is small-scale, largely from the originating group, and unreplicated.

Examine

No Examine.com article on Epitalon exists.

ConsumerLab

No ConsumerLab article on Epitalon exists.

Systematic Reviews

No systematic reviews or meta-analyses for Epitalon were found on PubMed as of 09/30/2026.

Mechanism of Action

Epitalon is a four-amino-acid peptide (alanine-glutamate-aspartate-glycine) designed from the amino acid makeup of epithalamin, a bovine pineal extract. Its proposed actions remain largely unconfirmed in people.

  • Telomerase activation: In cultured human cells epitalon raised telomerase activity and lengthened telomeres (Khavinson et al., 2003); an independent group confirmed lengthening in normal cells and, through ALT, in breast cancer cells (Al-Dulaimi et al., 2025).
  • Pineal and melatonin modulation: Old monkeys showed higher night melatonin after treatment (Goncharova et al., 2005), but a Paris laboratory study found no effect on melatonin release by isolated rat pineal tissue in vitro (Djeridane et al., 2003); the difference may reflect species and test system (intact aged primates versus isolated rat tissue).
  • Gene regulation and antioxidant action: Modeling suggests binding to histones (proteins that package genetic material), which may alter gene expression (Khavinson et al., 2020); antioxidant effects were shown in cell models (Yue et al., 2022).

Pharmacology: No human data exist on how the body absorbs, distributes, or clears it. Short peptides are expected to be cut into amino acids by peptidases (enzymes that break down proteins) rather than metabolized by CYP enzymes (liver enzymes that process most drugs). Half-life, tissue distribution, and receptor selectivity are unmeasured, and no receptor has been identified.

Historical Context & Evolution

Epitalon grew out of Soviet and Russian research on aging. From the 1970s, Vladimir Khavinson’s group in St. Petersburg studied epithalamin, an extract of cattle pineal glands, on the idea that the pineal gland weakens with age and that its peptides help regulate other tissues (Khavinson, 2002). Amino acid analysis of the extract led to the synthetic tetrapeptide, and the same sequence was later detected in pineal peptide mixtures (Khavinson et al., 2017).

Interest in health optimization followed reports of longer lifespan in fruit flies (Khavinson et al., 2000) and mice (Anisimov et al., 2003), telomerase induction in human cells (Khavinson et al., 2003), and lower mortality with the extract in older adults (Korkushko et al., 2006).

Nearly all of this work came from one research network. Animal results were mixed: average lifespan was unchanged in some strains while maximum lifespan rose. Differences in strain, sex, and lighting regime (effects appeared mainly under constant or natural northern lighting, per Vinogradova et al., 2007) may explain the divergence, and tumor results varied with the model: fewer chemically induced colon (2002) and transgenic (genetically engineered) mammary (2002) tumors, but no change in total spontaneous tumors in outbred mice (2003). What changed recently is that a UK group independently reproduced telomere lengthening but also observed it in cancer cells (Al-Dulaimi et al., 2025), and regulators began reviewing epitalon for pharmacy preparation. Neither development settles what the human evidence supports.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint or validated surrogate (a measurable stand-in for a health outcome) has been shown in more than one controlled human trial (with a comparison group) of epitalon itself.

Medium 🟩 🟩

No benefit reaches Medium: the human data on epitalon itself are small, unreplicated reports from its developing laboratory, and the controlled outcome trials tested the parent pineal extract epithalamin.

Low 🟩

Lower Mortality and Slower Cardiovascular Aging (Pineal Extract Epithalamin)

Long-term controlled trials of the parent pineal extract, not synthetic epitalon, in older adults reported slower cardiovascular aging and lower mortality (Korkushko et al., 2006; Khavinson & Morozov, 2003). The trials came from the developing network and lack independent replication.

Magnitude: Deaths were 28% lower over 12 years and cardiovascular deaths about 2-fold lower with the extract than with basic therapy alone (Korkushko et al., 2006).

Retinal Function in Retinitis Pigmentosa ⭕️ Not Central to Health & Longevity

Retinitis pigmentosa (an inherited disease in which light-sensing retinal cells gradually die) was studied. A developer-authored report described a positive clinical effect in patients, with no comparison group described for the human part. This bears on a rare eye disease, not general longevity.

Magnitude: A positive clinical effect was reported in 90% of treated patients; the abstract gives no effect size, visual measure, or patient count (Khavinson et al., 2002).

Speculative 🟨

Melatonin Rhythm in Older Adults ⚠️ Conflicted

Developer-network studies report higher night melatonin in adults with low pineal output (2007; 2020); an in-vitro Paris study of isolated rat pineal tissue found none (2003). Net reading: reported only by the originating network.

Sleep Quality and Insomnia

Epitalon is proposed to improve sleep by restoring night melatonin; the US Food and Drug Administration (FDA) reviewed it for insomnia (McDermott law-firm summary). The basis is mechanistic and anecdotal; no controlled human trial exists.

Telomere Lengthening in Cultured Human Cells

Epitalon lengthened telomeres in the developer’s laboratory (2003) and in an independent UK study (2025). No human outcome data exist, and telomere length is not a validated stand-in for health outcomes.

Lifespan Extension in Animals ⚠️ Conflicted

Epitalon lengthened lifespan in fruit flies (2000) and mainly maximum lifespan in mice (2003). Average lifespan was unchanged in rats under standard lighting (2007). Net reading: modest, inconsistent gains from one network.

Fewer Tumors in Rodent Models ⚠️ Conflicted

Developer-network studies report fewer chemically induced colon (2002) and transgenic mammary (2002) tumors in rodents, yet total spontaneous tumor incidence was unchanged in outbred mice (2003). Net reading: variable and unproven in people.

Cytoprotection in Cell Models ⭕️ Not Central to Health & Longevity

Epitalon reduced oxidative stress (reactive oxygen damage) in mouse egg cells (Yue et al., 2022) and aided retinal cell wound healing (Gatta et al., 2025). These findings bear on cell biology, not whole-body longevity.

Glucose Handling in Aged Monkeys

Old rhesus monkeys given epitalon showed lower fasting glucose and insulin and faster glucose clearance, while young monkeys did not change (Goncharova et al., 2005). No human data exist.

Neuroprotective Signals in Cell and Rodent Models

Epitalon raised neuronal differentiation markers in cultured human stem cells (Khavinson et al., 2020) and cortical neuron firing in anesthetized rats (Sibarov et al., 2007). No human cognitive outcome data exist.

Immune Modulation in Animal and Cell Studies

A narrative review describes changed interleukin-2 (an immune-signaling protein) expression and thymocyte (immature immune cell) activity with epitalon in mouse studies (Araj et al., 2025). No human immune outcome data exist.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic or gene-variant data exist for epitalon; variants in telomere-maintenance genes are a theoretical modifier only.
  • Baseline biomarkers (measurable indicators such as blood tests): Night melatonin rose with the parent extract mainly in older adults whose pineal activity was initially low (Korkushko et al., 2004); old, not young, monkeys showed glucose and melatonin changes.
  • Sex differences: No sex-stratified human data exist; animal lifespan work used mainly female mice and rats, with male rats showing tumor but not lifespan changes (Vinogradova et al., 2008).
  • Pre-existing conditions: Reports involved coronary disease (extract) and retinal degeneration (epitalon); effects in otherwise healthy adults have not been measured in controlled trials.
  • Age: Effects were reported in older animals and adults; younger adults are the least studied group, and benefit at the older end of the range rests on developer-network trials of the extract.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event of epitalon has been documented in more than one controlled human trial.

Medium 🟥 🟥

No risk reaches Medium: no single controlled human trial or consistent observational dataset documents an adverse event of epitalon.

Low 🟥

Unverified Product Identity and Purity

Epitalon is sold as an unapproved research product, and a regulatory laboratory identified it in illegal preparations (Vanhee et al., 2015). FDA reviewers judged it insufficiently characterized (Mintz law-firm summary), and a pharmacy-compounding (custom drug preparation) review discusses these concerns (Willis & Vu, 2026).

Magnitude: Not quantified in available studies. No published survey has measured purity, contamination, or mislabeling rates of marketed epitalon.

Speculative 🟨

Immune and Injection-Site Reactions

FDA cited immunogenicity (potential to provoke an immune response) among its safety concerns when it restricted such peptides from compounding (McDermott law-firm summary). No human adverse-event data specific to epitalon exist.

Cancer Promotion via Telomere Maintenance ⚠️ Conflicted

Telomerase or ALT activation could theoretically help tumor cells persist, and epitalon lengthened telomeres in breast cancer cell lines (Al-Dulaimi et al., 2025). Rodents showed fewer tumors instead. Net reading: unresolved, with no human data.

Lower Night Melatonin with Normal Pineal Function

In older adults with normal pineal function, night melatonin tended to fall after the parent extract (Korkushko et al., 2004). Whether epitalon does this is untested, and melatonin level is an unvalidated biomarker.

Unstudied Long-Term and Reproductive Safety

No human study of absorption and clearance, long-term use, or pregnancy safety exists. Mice given chronic low doses showed no toxicity (Anisimov et al., 2003).

Risk-Modifying Factors

  • Genetic polymorphisms: No gene-variant data exist for adverse effects; variants affecting telomere maintenance or immune response are theoretical modifiers only.
  • Baseline biomarkers: Adults with normal baseline night melatonin showed a tendency toward lower levels with the parent extract (Korkushko et al., 2004); baseline glucose and inflammation markers are unstudied as modifiers.
  • Sex differences: No sex-stratified safety data exist; pregnancy and breastfeeding are unstudied.
  • Pre-existing conditions: Cancer history, immune suppression, and use of glucose-lowering drugs plausibly raise risk on theoretical grounds.
  • Age: Safety in adults over 60 comes from developer-network reports of the extract; safety in people under 18 is unstudied.

Key Interactions & Contraindications

No formal interaction study of epitalon exists; every entry below is inferred from animal or mechanistic data.

  • Blood-sugar-lowering medications (metformin, insulin, glipizide), monitor: Epitalon lowered glucose and insulin in old monkeys (Goncharova et al., 2005), so additive low blood sugar (hypoglycemia) is theoretical. Fasting glucose checks during a course are the described precaution.
  • Immunosuppressants (drugs that dampen immune activity: tacrolimus, mycophenolate, prednisone), caution: Immune-cell effects in animal studies, summarized in a narrative review (Araj et al., 2025), leave the impact on transplant or autoimmune treatment unknown. Prior review with the treating specialist is the usual mitigation.
  • Cancer treatments (cisplatin, tamoxifen, radiotherapy), caution: Telomere effects on tumor cells are theoretical, and epitalon was paired with a second agent against senescent (aged, non-dividing) lymphoma (blood cancer) cells in mice (Zhang et al., 2026); interactions are unpredictable.
  • Sedative-hypnotics (sleep medications: zolpidem, eszopiclone), monitor: Melatonin-related effects could shift sleep timing or depth. Separating dose timing has not been studied.
  • Over-the-counter sleep aids (diphenhydramine, doxylamine), monitor: Overlapping night-time effects are possible but unstudied; no other over-the-counter interaction is documented.
  • Melatonin supplements, monitor: Both act on night melatonin exposure, so effects may add; tracking sleep and stopping one at a time clarifies attribution.
  • Telomerase-targeting supplements (cycloastragenol, TA-65, astragalus extract), caution: Overlapping telomerase claims raise the same theoretical tumor concern additively; no combination data exist.
  • Other injectable peptides (thymalin, BPC-157, TB-500, Semax), caution: Frequently co-used, but adverse events cannot be attributed to one agent; introducing one new agent at a time is the described mitigation.
  • Disrupted lighting and shift work, monitor: Rodent effects appeared mainly under constant or natural northern lighting (Vinogradova et al., 2007), so context may modify response; this is not a contraindication.

Populations who should avoid Epitalon:

  • Active cancer or cancer treated within the past 5 years (theoretical telomere-maintenance concern)
  • Pregnancy or breastfeeding (no safety data)
  • Age under 18 years (no safety data)
  • Solid-organ transplant recipients or others on immunosuppressants (unknown immune effects)
  • Prior allergic reaction to a peptide injection or to any component of the preparation

Risk Mitigation Strategies

  • Verified sourcing: An independent certificate of analysis showing identity by mass spectrometry (molecular-weight matching), purity of at least 98%, and endotoxin (bacterial fragments that trigger inflammation) and sterility results mitigates the identity and contamination risk.
  • Aseptic injection technique: Single-use syringes, an alcohol-wiped vial stopper, and rotating subcutaneous (under-the-skin) sites reduce infection and injection-site reactions.
  • Short defined courses: Limiting exposure to 10–20 days, with at least 3 months between courses, limits cumulative exposure while long-term safety is unstudied.
  • Cancer screening first: Confirming age-appropriate screening (colonoscopy, mammography, skin checks) is current before a first course addresses the theoretical tumor-promotion concern.
  • One new agent at a time: Starting epitalon alone, 4 weeks before any other new peptide or supplement, makes reactions attributable to one agent.
  • Glucose and sleep tracking: Fasting glucose at baseline and at course end, plus a sleep diary, detects glucose shifts and melatonin-related sleep changes.
  • Adverse-event reporting: Recording lot numbers and reporting reactions to MedWatch (the FDA’s voluntary adverse-event program) offsets the lack of safety data.

Therapeutic Protocol

  • Commonly circulated course: 5–10 mg by subcutaneous injection (under the skin) or intramuscular injection (into muscle) daily for 10–20 days, repeated one to three times yearly; extrapolated from extract trials using six courses over three years (Korkushko et al., 2011).
  • Competing approaches: Developer-style short courses contrast with lower-dose extended schedules in vendor and clinic guides; intranasal delivery (through the nose) has been tested only in rats (Sibarov et al., 2007). None has been compared head to head.
  • Who popularized it: Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology; Vladimir Anisimov for rodent work; O. V. Korkushko’s team in Kyiv for extract trials.
  • Time of day: Evening administration is commonly described to match the night melatonin peak seen in monkeys between 10 p.m. and 3 a.m. (Goncharova et al., 2003); no trial compared timings.
  • Half-life: No human half-life has been measured. Peptidase breakdown suggests short plasma persistence, so the duration of effect after a course is unexplained.
  • Single versus split dosing: The circulated course uses one daily dose; some vendors split it into morning and evening doses. No comparison exists.
  • Genetic polymorphisms: No variant is known to influence response or dose; telomere-maintenance and melatonin-pathway genes are untested.
  • Sex differences: No sex-stratified response or dosing data exist in humans.
  • Age: Effects appeared in old but not young monkeys (Goncharova et al., 2003), suggesting protocols aimed at younger adults extrapolate beyond the data.
  • Baseline biomarkers: Low baseline night melatonin was the condition under which increases were reported; no target values guide dose choice.
  • Pre-existing conditions: Coronary disease (extract) and retinal degeneration (epitalon) were the studied conditions; response in other conditions is unknown.

Discontinuation & Cycling

  • Duration: Use is designed as repeated short courses rather than lifelong daily exposure; how long effects persist between courses is unmeasured.
  • Withdrawal effects: None have been documented in animal or human reports.
  • Tapering: No tapering protocol is described or expected to be needed for a 10–20-day course.
  • Cycling: Courses spaced roughly 3–6 months apart are the circulated schedule; the extract trials used two courses yearly (Korkushko et al., 2011). Whether cycling maintains efficacy is untested.

Sourcing and Quality

  • Chemical forms: The sequence is Ala-Glu-Asp-Gly, molecular weight about 390 daltons; the free base and acetate salt were both reviewed by regulators (McDermott law-firm summary).
  • Identity and purity checks: Batch-specific certificates of analysis from independent laboratories typically show mass-spectrometry identity, purity of at least 98%, and endotoxin and sterility results; without one, content is unverified.
  • Supply channels: Research-chemical vendors label products “not for human use”; licensed compounding pharmacies become a possible channel only if listing proceeds. A Belgian analysis found epitalon in illegal preparations (Vanhee et al., 2015).
  • Brands and pharmacies: No brand or pharmacy has been validated by independent comparison; trials used the developer’s Epitalon® product (Anisimov et al., 2002), whose market availability is undocumented.
  • Storage: Lyophilized (freeze-dried) powder is generally kept cold and dry; reconstituted solutions are refrigerated and used within weeks, per vendor convention rather than published stability data.

Practical Considerations

  • Time to effect: No controlled human data exist. Monkey melatonin changes followed a 7–10-day course (Goncharova et al., 2003); rodent lifespan effects took months; reported sleep changes are anecdotal.
  • Common pitfalls: Buying unlabeled research vials, treating noisy consumer telomere tests as proof of benefit, starting several new peptides at once, and extrapolating animal lifespan gains to people.
  • Regulatory status: Not FDA-approved. An FDA advisory committee, whose voting members included industry representatives, narrowly recommended in July 2026 adding it to the pharmacy-compounding list (federal Section 503A), against FDA staff advice; rulemaking is pending (McDermott law-firm summary).
  • Cost and accessibility: No approved product exists; access is via research-chemical vendors or, if listing proceeds, prescription compounding. Prices are undocumented in the literature.

Interaction with Foundational Habits

  • Sleep: Direction: potentiating, indirect. Epitalon is proposed to restore night melatonin, and insomnia was the use FDA reviewed (McDermott law-firm summary), but no controlled sleep trial exists. Rat effects appeared mainly under disrupted lighting (Vinogradova et al., 2008), so dark evening routines fit the proposed mechanism.
  • Nutrition: Direction: none known. Glucose and insulin fell in old monkeys (Goncharova et al., 2005), so fasting or low-carbohydrate diets could stack glucose lowering; no dietary requirement or nutrient depletion is documented.
  • Exercise: Direction: none known. No study examined training, recovery, or muscle outcomes, so no timing around workouts has a basis in data.
  • Stress management: Direction: indirect. In rats, epitalon altered pineal activity only under stress, never at rest (Sibarov et al., 2002); no human stress-outcome data exist.

Monitoring Protocol & Defining Success

Baseline: No published target values exist for epitalon, so testing before a first course establishes personal reference points for glucose regulation, blood counts, inflammation, night melatonin, and optionally telomere length, alongside confirmation that age-appropriate cancer screening is current.

Ongoing: Repeat glucose regulation markers, blood counts, and inflammation markers at the end of each course (about 2–4 weeks after starting), again at 3 months, then every 6–12 months. Repeat night melatonin 2–4 weeks after a course, and telomere length no more often than every 12 months in the same laboratory. None of these is a validated success marker, so results are personal trends, not proof of benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–90 mg/dL Glucose handling changed in aged monkeys Conventional range 70–99 mg/dL; 8–12 hour fast, morning draw
HbA1c 4.6–5.3% Three-month glucose average HbA1c is glycated hemoglobin (hemoglobin coated with sugar); conventional under 5.7%; anemia can distort it
Fasting insulin 2–6 µIU/mL Insulin response normalized in old monkeys Conventional up to about 25 µIU/mL; same fasting draw as glucose
Complete blood count with differential White cells 4.5–7.0 ×10³/µL, no abnormal differential Immune effects seen in animals Conventional white cells 4.0–11.0 ×10³/µL; baseline abnormalities may exclude use
hs-CRP Under 1.0 mg/L General inflammation marker hs-CRP is high-sensitivity C-reactive protein; conventional under 3.0 mg/L; avoid testing during infection
Night melatonin (saliva or urinary 6-sulfatoxymelatonin) No established target; track change from own baseline The main marker reported to shift 6-sulfatoxymelatonin is the main urinary melatonin breakdown product; dim-light sampling near 10 p.m.–midnight; stop melatonin supplements for several days first
Blood telomere length (optional) No established target; track change from own baseline The intended target of telomerase claims Assay variability is large; use the same laboratory and method; not validated against outcomes

Qualitative markers to track:

  • Sleep quality, sleep onset, and morning refreshment
  • Daytime energy and mood
  • Cognitive clarity and stress resilience
  • Injection-site tolerance and any new symptoms

Emerging Research

  • Registered trials: No epitalon trials are registered on ClinicalTrials.gov (searches for epitalon, epithalon, AEDG (the peptide’s amino acid code), and epithalamin returned no records), so no ongoing human trial can be cited; the FDA review considered insomnia as the proposed use (McDermott law-firm summary).
  • Independent replication (strengthens): The 2025 UK cell study is an independent confirmation of telomere lengthening in human cells (Al-Dulaimi et al., 2025); a published correction followed (Correction, 2025).
  • Cancer-cell safety question (weakens): Lengthening also occurred in cancer cells through ALT (Al-Dulaimi et al., 2025), and a 2026 study paired epitalon with a second agent to partially clear senescent lymphoma cells (aged, non-dividing cells of a blood cancer) in mice (Zhang et al., 2026); tumor risk in people is untested.
  • Retinal disease models: Epitalon restored wound healing in high-glucose retinal cells, a model of diabetic retinopathy (diabetes-related retinal damage) (Gatta et al., 2025); human relevance is unknown.
  • Regulatory decision: FDA rulemaking on the pharmacy-compounding list is pending after the narrow advisory vote; the McDermott law-firm summary that reports this is written for compounders, prescribers, and marketers (McDermott law-firm summary).
  • Known gaps: A 2026 narrative review lists missing long-term safety data, dosing regimens, and monitoring biomarkers for epitalon and related peptides (Mavrych et al., 2026).

Conclusion

Epitalon is a synthetic four-amino-acid chain, developed in Russia from a pineal gland extract, used by health- and longevity-oriented adults mainly as an injectable research product. The evidence base is thin and narrow. No benefit reaches high or medium confidence: human data on epitalon itself are small reports from its developers, the larger controlled trials with survival results used the parent extract, and lifespan, tumor, and chromosome-cap findings come from animals and cultured cells, often with mixed results. An independent laboratory has confirmed longer chromosome-end caps in cultured human cells, but the same work showed lengthening in cancer cells, and no human study has measured whether this matters for health.

Reported risks are mostly theoretical or concern product quality: unverified identity and purity, unassessed immune reactions, uncertain long-term safety, and a possible cancer concern. None reaches high confidence, and most rest on missing data rather than observed harm.

Most of the research comes from the group that created epitalon and has a direct interest in its adoption, while regulatory staff recommended against listing. The regulatory picture remains unsettled. For this audience, the case rests on plausible mechanisms and early signals rather than demonstrated effects on health or longevity.

Top - Benefits - Risks - Protocol